GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
Compound class:
Synthetic organic
Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Epitinib is in early stage clinical evaluation for anti-tumour potential. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | Phase 1 Interventional | Hutchison Medipharma Limited | ||
| NCT02590952 | A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors | Phase 1 Interventional | Hutchison Medipharma Limited | ||